These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 21566513)

  • 1. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.
    Yang Z; Tang LH; Klimstra DS
    Am J Surg Pathol; 2011 Jun; 35(6):853-60. PubMed ID: 21566513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.
    Tang LH; Gonen M; Hedvat C; Modlin IM; Klimstra DS
    Am J Surg Pathol; 2012 Dec; 36(12):1761-70. PubMed ID: 23026928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors.
    Dhall D; Mertens R; Bresee C; Parakh R; Wang HL; Li M; Dhall G; Colquhoun SD; Ines D; Chung F; Yu R; Nissen NN; Wolin E
    Hum Pathol; 2012 Apr; 43(4):489-95. PubMed ID: 21937080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.
    Strosberg J; Nasir A; Coppola D; Wick M; Kvols L
    Hum Pathol; 2009 Sep; 40(9):1262-8. PubMed ID: 19368957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma.
    Stroescu C; Dragnea A; Ivanov B; Pechianu C; Herlea V; Sgarbura O; Popescu A; Popescu I
    J Gastrointestin Liver Dis; 2008 Dec; 17(4):411-7. PubMed ID: 19104702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KI67 proliferation index in tumors of the upper urinary tract as related to established prognostic factors and long-term survival.
    Rey A; Lara PC; Redondo E; Valdés E; Apolinario R
    Arch Esp Urol; 1998 Mar; 51(2):204-10. PubMed ID: 9586325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease.
    Singh S; Hallet J; Rowsell C; Law CH
    Eur J Surg Oncol; 2014 Nov; 40(11):1517-22. PubMed ID: 25088936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms.
    Lin O; Olgac S; Green I; Zakowski MF; Klimstra DS
    Am J Clin Pathol; 2003 Aug; 120(2):209-16. PubMed ID: 12931551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
    Remes SM; Tuominen VJ; Helin H; Isola J; Arola J
    Am J Surg Pathol; 2012 Sep; 36(9):1359-63. PubMed ID: 22895268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Grading the neuroendocrine tumors of the lung: an evidence-based proposal.
    Rindi G; Klersy C; Inzani F; Fellegara G; Ampollini L; Ardizzoni A; Campanini N; Carbognani P; De Pas TM; Galetta D; Granone PL; Righi L; Rusca M; Spaggiari L; Tiseo M; Viale G; Volante M; Papotti M; Pelosi G
    Endocr Relat Cancer; 2014 Feb; 21(1):1-16. PubMed ID: 24344249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
    Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
    Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study.
    Elias D; Lasser P; Ducreux M; Duvillard P; Ouellet JF; Dromain C; Schlumberger M; Pocard M; Boige V; Miquel C; Baudin E
    Surgery; 2003 Apr; 133(4):375-82. PubMed ID: 12717354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria.
    Huang HY; Huang WW; Lin CN; Eng HL; Li SH; Li CF; Lu D; Yu SC; Hsiung CY
    Ann Surg Oncol; 2006 Dec; 13(12):1633-44. PubMed ID: 17013685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis.
    Li SS; Xue WC; Khoo US; Ngan HY; Chan KY; Tam IY; Chiu PM; Ip PP; Tam KF; Cheung AN
    Histopathology; 2005 Mar; 46(3):307-13. PubMed ID: 15720416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
    Van Eeden S; Quaedvlieg PF; Taal BG; Offerhaus GJ; Lamers CB; Van Velthuysen ML
    Hum Pathol; 2002 Nov; 33(11):1126-32. PubMed ID: 12454818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas.
    Colman H; Giannini C; Huang L; Gonzalez J; Hess K; Bruner J; Fuller G; Langford L; Pelloski C; Aaron J; Burger P; Aldape K
    Am J Surg Pathol; 2006 May; 30(5):657-64. PubMed ID: 16699322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas.
    Hentic O; Couvelard A; Rebours V; Zappa M; Dokmak S; Hammel P; Maire F; O'Toole D; Lévy P; Sauvanet A; Ruszniewski P
    Endocr Relat Cancer; 2011 Feb; 18(1):51-9. PubMed ID: 20959440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.